Welcome to CienciaPR, an expert and resource network for all who are interested in science and Puerto Rico.
Dr. Carlos A. Molina obtained a B.S. Magna Cum Laude in Biology at the Biology Department, School of Science of the University of Puerto Rico, Rio Piedras, Puerto Rico in 1985. In 1991 he was conferred a Ph.D. degree in Biochemistry at the Department of Medicinal Chemistry, School of Pharmacy of Purdue University, West Lafayette, Indiana. From 1992-1994 he performed Post-Doctoral studies in CNRS-LGME, Institut De Chimie Biologique Faculte De Medicine, Strasbourg, France. During his predoctoral, doctoral and postdoctoral years he received several awards and honors. Presently Dr. Molina is an assistant professor at the Department of Obstetrics and Gynecology, New Jersey Medical School, Newark, New Jersey. His research interest includes: 1) the mechanisms involved in the transcriptional response to the cAMP-mediated signal transduction, 2) regulation of cell growth through hormonal action; particularly, how activation of the cAMP pathway affects the cell cycle, 3) application of the results obtained from molecular and cellular experimentation to animal models, and 4) gene expression in reproductive systems.
Dr. Molina works with a protein termed ICER. His laboratory discovered that ICER controls the growth of normal cells. In certain cancer cells ICER protein is not present. When ICER protein is introduced into these cancer cells, they become more like normal cells. The discovery of this phenomenon is important because it could lead to the development of new treatments for cancer. In particular, Dr. Molina’s recent work, suggests that ICER acts as a tumor suppressor in prostate cancer cells. This work has led to further studies into prostate cancer. Presently, Dr. Molina is developing animal models to study the role of ICER in the treatment of cancer. These in vivo systems are used to test new cancer treatment and the effectiveness of known cancer treatment modalities. The long-term goal of Dr. Molina's laboratory is to use the ICER-null and transgenic mice as a model system for the treatment of human cancers.
Find resources related to scientific publications
See our funding feeds from the NIH and the NSF
See our jobs feeds from various sources.